Transforming life for patients with Parkinson’s disease
Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.
Two clinical phase II candidates
Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >
Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >
Proprietary technology platform
The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >
Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease.
IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetamJuly 16, 2021
IRLAB (Nasdaq Stockholm: IRLAB A) announced late yesterday that a licensing agreement has been entered with the global biopharmaceutical company Ipsen for the drug candidate mesdopetam. In connection with this, IRLAB invites investors, analysts and media to a conference call on July 16, 2021, at 10:00 CET.Read More >
CEO Nicholas Waters, CEO, participated at Redeye Growth Day 2021June 2, 2021
Nicholas Waters, CEO, presented at Redeye Growth Day on June 2, 2021. The presentationen is followed by a Q&A and is held in English. Watch here >Read More >